Progression Of Cancer Is An Intricate Multi-Step Process Assignment Sample

• Type Assignment
• Downloads531
• Pages13
• Words3332

Chapter 1: Introduction to Progression Of Cancer Is An Intricate Multi-Step Process Assignment Sample

Cancer is not a process of acquiring specific features and becoming cancerous but a constantly evolving process where the malignant cells as well as the microenvironment of the cancer, are transformed. We do know that some proto oncogenes are formed due to mutations that lead to uncontrolled cell division while there are stroma derived from normal tissue cells which in one way support the growth and survival of cancer cells. It is important to establish the cancer cell-biomolecule contacts, blood circulation, and other factors to diagnose the disease and identify the cause of treatment. Description such mechanisms would also enhance clinical prognosis and ease of cancer management and lead to the development of more tactics to prevent the advancement of the disease.

To support academic growth, we provide reference documents and sample papers that help students understand assignment structure and presentation standards. Being a professional assignment helper in UK, we focus on offering ethical guidance while maintaining plagiarism-free work. The Progression Of Cancer Is An Intricate Multi-Step Process Assignment Sample serves as an example to explain formatting, observations, and discussion. These samples are intended only for study and reference use.

1.2. Background of the study

Cancer is considered a disease that’s brought about by alterations in DNA, which leads to cell proliferation. However, the disease can be acquired hand in hand; in other words, the work presents some other symptoms associated with the disease. Stroma is one of the most significant components of the tumor microenvironment that plays an enormous role in tumorigenesis. It has blood vessels, immune cells, fibroblasts, and also some constituents of the extracellular matrix that support the growth and extension of cancer cells. There are points that genetic alteration that takes place within the cancer cells as well as the support from stromal cells do hinder tumor immune escape and enhance the possibilities of vascularization and invasion of the neighboring tissues. Understanding the process by which microenvironments promote carcinogenesis is conducive in biomarker identification, tumour staging, therapies intending to focus on the cell microenvironments and treatment planning.

Progression Of Cancer Is An Intricate Multi-Step Process Assignment Sample

Liked This Sample? Hire Me Now

David Moore 9 Years | MSc

1.3. Research Aim

This study’s purpose will be to explore the genetic instability and the tumor microenvironment as factors involved in cancer growth. This is done in order to assess how stroma affects malignant growth in order to advance human knowledge of cancer development and come up with better ways to detect, diagnose, and treat it.

1.4 Research Objectives

• To investigate if the tumor stroma plays a role in supporting tumor progression.
• To appreciate the link between cancer cells and the other stromal cells, which are present most of the times in the tumor mass.
• To contribute to the early diagnosis and consequently early treatment in cancer handling.

1.5 Research Questions

• What is the abiity of tumor stroma in the growth of the malignant cells?
• How does the partnership of the cancer cell to the microenvironment facilitates the progression of the disease?

1.6 Research Rationale

Cancer remains an endemic illness that eradicates many lives; the advancement of cancer is due to the activities of the cancer cells and the constituent cells of the tumor microenvironment. Today, they go through some challenges like relapse of the disease as well as the metastasis (Tan, and Naylor, 2022). Many people presume that one of the mostly causes of cancer is infiltration and mutations inside the tumor cells, however these cells cannot grow or metastasize without help of the stroma. The results also suggest that because the stroma of OA’s angiogenesis, modulated immune, and growth matrix, which play a significant role in it progression. Thus, tumor specialists can find first contacts in the cancer cells and stroma and not only the cancer cells but also surrounding supportive tissues. The findings of this paper will contribute to increasing the knowledge of the existing literature that will help make better efforts for establishing the better prevention strategy and therapy regarding cancer development and related deaths.

1.7 Research Significance

The significance of this study is based on the aspect of building up knowledge regarding the cancer cells mutation and the factors/conditions affecting its occurrence. There is still widespread treatment of cancer cells in the conventional treatment approaches, which means that most treatments end up making the cancer cells grow resistant and in return making the cancer come back (Neophytou et al. 2021). This study allows to define the role of the tumor stroma in supporting the tumor and to establish new objectives for treatment beyond current treatment options. It remains an important question considering that knowledge of how tumor-stroma crosstalk might modulate cancer development could potentially help in finding ways to treat cancer. Furthermore, the study may be helpful in locating certain biomarkers that can be used in the early diagnosis of cancer, thus helping diagnose it at the early stage (Mavatkar et al. 2023). Smarter patient care incorporated into the study will assist in clinical decision-making processes to enhance the establishment of more specialized and comprehensive procedures as a way of improving on the response to diseases and cancer, therefore, reducing mortality levels and improving the general performance of oncology treatment.

1.8 Conclusion

It can be concluded that cancer progression is obviously as a multistep process, which depends on genetics and the non-neoplastic stroma. Genetic instability is characteristic of cancer cells and is responsible for the uncontrolled proliferation of these cells, while the stroma promotes survival, invasion, and metastasis of cancer cells. This information helps in the development of new treatment options, early diagnosis, and even detecting relapse of the same disease. This is, in a way, possibly why future treatment strategies should focus on the interaction between tumor cells and their nonsmall cell lung cancer stroma, which could help in the development of novel treatment approaches that target not only carcinoma cells but also the base on which they reside.

Chapter 2: Review of Literature

Cancer as a phenomenon is vested in having stages that involve gradual genetic mutations in the tumor cells as well as dynamic changes in the nearby environment. This chapter focuses on the aspects of mutation and stroma support of tumor growth, metastatic process, and resistance to treatment. In this particular chapter, an attempt has been made to provide the readers with insights on the various mechanisms that underlie cancer progression based on such models as the Clonal Evolution Model, the Tissue Organization Field Theory, the Tumor Microenvironment Theory, and the Angiogenesis Model. Additionally, it points out the unsolved issues in literature, mainly the lack of knowledge regarding the relationship between tumor-stroma interaction and therapeutic response outcomes, and finally, the general goals to establish better treatments for cancer.

2.2. Empirical Study

According to Tirendi et al. 2023, CRC is the second most prevalent cancer in the world, and most of it is sporadic in nature and provoked by risk factors, including lifestyle, impaired gut microbiota, inflammation, and oxidative stress. This paper will therefore aim at providing an overview of the biology of CRC and assess current therapies with reference to chemoresistance. The procedures included the Pubmed database search using appropriate words such as colon cancer, treatment, chemoresistance, and oxidative stress, new formulations for administration, immunotherapy, and cancer stem cell. The studies were carried out in the years from 1988 to the year 2022, and further search was done using clinical trial databases. The findings suggest that radiotherapy, chemotherapy, and immunotherapy are effective in relieving the cancer recurrence rates and death rates and are essential to address for stage II, III, and IV CRC patients. Chemotherapy with 5-FU-based regimens is still considered the mainstream treatment (Tirendi et al. 2023). Chemotherapy is greatly frustrated by the development of chemoresistance, which can be inherent or acquired together with the existence of chemoresistant cancer stem cells. In a variation of genetic and molecular profiles, the latter complicates the effectiveness of newer treatment such as immunotherapy. Apart from drug discovery, it is important to recognize that CRC’s other processes have not been thoroughly studied, with drug resistance being only one of the crucial factors.

New strategies in the drug delivery systems and biomarkers would be a potential improvement on available treatments in advanced CRC. The study thus recommends that more studies be conducted in order to help address these challenges and enhance the well-being of patients.

According to Catalano et al. 2025, this research emphasizes issues such as the significance of reactive oxygen species in the general development of colorectal cancer, including formation and therapy resistance. ROS play a critical role in regulating several cellular activities such as cell division, cell repair, and cell death processes. Tumor cells gain oxidative phosphorylation metabolism and/or mutations that allow them to grow under conditions of high levels of ROS. Moreover, the cancer cells increase antioxidant defenses while increasing the source of ROS for proliferation purposes. Chemotherapy can increase oxidative stress and redox reactions as well as kill cancer cells and reduce drug metastasis. The study suggests that ROS manipulation could be the main avenue towards the therapy for CRC. Since ROS levels could be targeted, anticancer treatment must increase its effectiveness. The review focuses on the possibilities of ROS modulation in overcoming the therapy resistance in conjunction with the emphasis on CRC and the involvement of the altered signaling pathways. It also focuses on the place of ROS in CRC diagnosis and prognosis. The paper discusses the ROS implication in most treatment methods for CRC such as surgery, radiotherapy, chemotherapy, immunotherapy, theranostic imaging, and precision medicine (Catalano et al. 2025). These treatments may result in more specific and efficient therapies, especially in dealing with resistance to the available treatments. Hence, understanding and managing the ROS in the course of CRC could provide positive impacts with regard to treatment efficacy and resistance profile and can further lead to the development of better treatment approaches and plans that can contribute to the increase in the survival rate of the patients.

According to Poturnajova et al. 2021, CRC is accountable for 1.4 million new cases of cancer every year and accounts for 50% of CRC patients developing metastases during the course of the disease. It is established that metastatic CRC belongs to the category of terminal diseases, and the 5-year survival rate of patients who underwent resection of liver metastasis ranges from 25 to 58%. Sequencing data has greatly improved in recent years the knowledge on large sets of CRC patients and their primary tumors and metastases. Thus, through the gene and pathway comparison of primary CRC and metastases, researchers have been able to distinguish both early-onset genes in carcinogenesis as well as late-onset genes involved in the metastatic process. These genetic, transcriptional, and epigenetic changes encoded within the nominated genes affect this signaling to allow the tumor cells to migrate and proliferate in target organs. Accordingly, the work emphasizes the organization of CRC metastasis, indicating that all the mentioned changes contribute to cancer spread.

These results suggest that multiple pathways must be experimented to enhance the effectiveness of treatment outcomes. Mitotic genes for metastasis and drivers of CRC progression are particularly useful in developing improved management of metastatic CRC (Poturnajova et al. 2021). It may enhance the care to patients with advanced diseases, especially those with metastatic lesion, due to enhanced ability to select target and coordinate the treatments.

2.3. Theories and Models

Angiogenesis Model

The Angiogenesis Model as a theory is most relevant when defining the part played by blood vessel growth in cancer advancement. Solid tumors need a blood supply in order to grow to a certain size, and for this reason, the formation of new blood vessels is crucial for the tumors’ survival and metastatic progression (Pieniądz et al. 2024). Tumors influence angiogenesis by the secretion of pro-angiogenic factors that include the vascular endothelial growth factor necessary for the formation of new blood vessels. These new vessels are not only providing supply nutrients and oxgen to the growing tumor but also through which the cancer cells can go to the blood stream and invade other organs. There is the model of angiogenesis that highlights the aspect of blood vessels as a factor in tumor progression. Angiogenesis is a significant factor for tumor survival and metastasis, hence this process is a potential strategy for cancer treatment.

Clonal Evolution Model

The Clonal Evolution Model is one of the famous models that have been established to explain the genetics of cancer progression and was postulated by Peter Nowell in 1976. Through this model, cancer is believed to originate from a definite cell that goes through the process of mutation. This leads to the expansion of other genetic alterations that lead to the emergence of more clones within the tumor mass, which have different genetic profiles. Such sub-populations may differ in their level of malignancy and the ability to metastasize. On that basis of the clonal evolution model, it is important to understand cancer as a process and not a state and that changes in tumor cells are not singular but cumulative. As shown in this model, tumor progression stems from genetic heterogeneity, given that the fittest mutations by selective pressures include hypoxia, immune surveillance, and therapy (Orlow, 2024). The clonal evolution model describes how cancer progresses; that is how cancer cells progress in regard to the chronology of their malignancy, their invasion rate, and their ability to fight against cancer therapies. The understanding of clonal evolution helps to analyse cancer development not as a result of the increase in the number of mutations in the course of the benign cell’s evolution but as a result of interactions of genetic changes in heterogeneous population of tumour cells.

Tumor Microenvironment Theory

The Tumor Microenvironment Theory also goes in line with the earlier assertion that cancer development is highly influenced by the relations between the cancer cells and nearby stromal cells. The TME is a three-dimensional structure containing several nontransformed cells including fibroblasts, immune cells, endothelial cells, and ECM components that favor tumor growth and metastasis. TME is recognized to exert an influence on many aspects of cancer cells and therefore plays a significant role in tumour progression.

Accordingly, in this theory, tumor cells are shaped by both genetic changes within the cells as well as changes in the environment offered by the TME. CAF, immune cells to proliferate, invade, metastasize, and develop therapy resistance, as well as endothelial cells and the ECM. Chemokines, cytokines, and growth factors released or presented by the TME in turn help in the proliferation of cancer cells, the formation of new blood vessels, and immune evasion. the TME can also facilitate what is known as epithelial-mesenchymal transition, an important process in the spread of cancer cells.

Theory of Tissue Organiation Field

Tissue Organization Field Theory has been introduced by Foulds in the middle of the fifties and it is based on the idea that the changes in the macro environment of the tissue are responsible for the cancer development. They established from their theory known as the TOFT that cancer development depends not only on the genetic transformation of the cancer cell but also the alterations made on the normal surrounding stroma. The theory proposes that cancer arises from disturbances in the organization of the tissue and cell communication, modifying the normal process of tissue organization. In this model, the cancer cells are not just an independent entity but a part of a tissue-independent system which is out of control (Ni et al. 2023). This dysregulation may be attributed to genetic abnormalities in the cancer cells as well as in the surrounding stroma, including fibroblasts, densities, matrix, or inflammatory elements. In the context of the TOFT model, the tumor stroma contributes to another step; that is, it helps in forming an environment conducive for tumor growth, which involves fostering angiogenesis and immune escape and supplying growth factors.

2.4 Literature Gap

From the presented literature gaps in these studies, the following can be pinpointed as subjects which require further analysis: First, although chemotherapy and immunotherapy have been already used for CRC treatment, the mechanisms that determine chemoresistance, especially associated with CSCs, are poorly understood (Ledda et al. 2023). It is essential to advance knowledge about genetic and molecular changes associated with CRC that hinder the application of such advancements. In this respect, despite the effectiveness of drug delivery systems, there is a need for enhancement regarding state-of-the-art treatment options against CRC. Many research need to be proceeded bsed on the modulation of ROS which are specifically recognised in the development of CRC.

2.5 Conclusion

In conclusion, it is possible to state that the processes of cancer progression involve both genetic features and the functions of the TME. The recent empirical data presented describe the specific interactions of cancer cells with the structures around the tumor that provide its sustenance, propagation and spreading. In this regard, the described models and theories are helpful for understanding the cancerogenesis process from the perspectives of cells and their microenvironment. However, as the current paper has pointed out, there are still many unknowns left, especially in applying these theories in an effort to create new and better therapeutic approaches. As highlighted above, the above areas will be very important in making strides in precision medicine and contributing towards a definite end to the problems that originate from therapy resistance and metastasis in the treatment of cancer to enhance the lives of patients who have the misfortune of getting this disease.

Reference List

Journals

• Catalano, T., Selvaggi, F., Cotellese, R. and Aceto, G.M., 2025. The Role of Reactive Oxygen Species in Colorectal Cancer Initiation and Progression: Perspectives on Theranostic Approaches. Cancers, 17(5), p.752.
• El-Tanani, M., Rabbani, S.A., Babiker, R., Rangraze, I., Kapre, S., Palakurthi, S.S., Alnuqaydan, A.M., Aljabali, A.A., Rizzo, M., El-Tanani, Y. and Tambuwala, M.M., 2024. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters, p.216894.
• He, S., Zhou, C., Peng, H. and Lin, M., 2021. Recent advances in fecal gene detection for colorectal cancer diagnosis. Biomarkers in Medicine, 15(14), pp.1299-1308.
• Kasprzak, A., 2023. Prognostic biomarkers of cell proliferation in colorectal cancer (CRC): From immunohistochemistry to molecular biology techniques. Cancers, 15(18), p.4570.
• Ledda, M., Pluchino, A. and Ragusa, M., 2023. Colorectal cancer as a model for biological evolution. bioRxiv, pp.2023-04.
• Liang, D., Liu, L., Zhao, Y., Luo, Z., He, Y., Li, Y., Tang, S., Tang, J. and Chen, N., 2023. Targeting extracellular matrix through phytochemicals: a promising approach of multi-step actions on the treatment and prevention of cancer. Frontiers in Pharmacology, 14, p.1186712.
• Mavatkar, A.D., Naidu, C.M., Prabhu, J.S. and Nair, M.G., 2023. The dynamic tumor–stromal crosstalk: implications of ‘stromal-hot’tumors in the process of epithelial–mesenchymal transition in breast cancer. Molecular Biology Reports, 50(6), pp.5379-5393.
• Neophytou, C.M., Panagi, M., Stylianopoulos, T. and Papageorgis, P., 2021. The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. Cancers, 13(9), p.2053.
• Ni, Y., Liang, Y., Li, M., Lin, Y., Zou, X., Han, F., Cao, J. and Li, L., 2023. The updates on metastatic mechanism and treatment of colorectal cancer. Pathology-Research and Practice, 251, p.154837.
• Niu, Y., Yang, W., Qian, H. and Sun, Y., 2022. Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated. Cancer Cell International, 22(1), p.341.
• Orlow, I., 2024. Molecular Mechanism of Carcinogenesis: Insight into Tumor Initiation and Progression. Journal of Carcinogenesis, 23(1).
• Pieniądz, P., Pięt, M. and Paduch, R., 2024. Characteristics of the Colorectal Cancer Microenvironment—Role in Cancer Progression and Therapeutic Possibilities. Applied Sciences, 14(7), p.2930.
• Poturnajova, M., Furielova, T., Balintova, S., Schmidtova, S., Kucerova, L. and Matuskova, M., 2021. Molecular features and gene expression signature of metastatic colorectal cancer. Oncology Reports, 45(4), p.10.
• Ren, J.X., Chen, L., Guo, W., Feng, K.Y., Cai, Y.D. and Huang, T., 2024. Patterns of gene expression profiles associated with colorectal cancer in colorectal mucosa by using machine learning methods. Combinatorial Chemistry & High Throughput Screening, 27(19), pp.2921-2934.
• Tan, K. and Naylor, M.J., 2022. Tumour microenvironment-immune cell interactions influencing breast cancer heterogeneity and disease progression. Frontiers in Oncology, 12, p.876451.
• Tirendi, S., Marengo, B., Domenicotti, C., Bassi, A.M., Almonti, V. and Vernazza, S., 2023. Colorectal cancer and therapy response: a focus on the main mechanisms involved. Frontiers in oncology, 13, p.1208140.
• Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., Tao, Q. and Xu, H., 2022. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Molecular cancer, 21(1), p.144.